BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Costa MB, Picon PD, Sander GB, Cuni HN, Silva CV, Meireles RP, Góes ACMA, Batoreu NM, Maia MLS, Albuquerque EM, Matos DCS, Saura PL. Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. BMC Pharmacol Toxicol 2018;19:1. [PMID: 29301580 DOI: 10.1186/s40360-017-0192-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Erba A, Beuret M, Daly ML, Khanna N, Osthoff M. OPAT in Switzerland: single-center experience of a model to treat complicated infections. Infection 2020;48:231-40. [PMID: 31828605 DOI: 10.1007/s15010-019-01381-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Thompson NK, LeClaire LTN, Rodriguez Perez S, Wakarchuk WW. Investigation of sequon engineering for improved O-glycosylation by the human polypeptide N-acetylgalactosaminyl transferase T2 isozyme and two orthologues. Biochem J 2021;478:3527-37. [PMID: 34523671 DOI: 10.1042/BCJ20210382] [Reference Citation Analysis]
3 Ullah Z, Sonawane PM, Mary YS, Mary YS, Yohannan Panicker C, Churchill DG. A foundational theoreticalAl 12 E 12 (E = N, P) adsorption and quinolone docking study: cage–quinolone pairs, optics and possible therapeutic and diagnostic applications. Journal of Biomolecular Structure and Dynamics. [DOI: 10.1080/07391102.2022.2053742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 da Silva AMV, Alvarado-Arnez LE, Azamor T, Batista-Silva LR, Leal-Calvo T, Bezerra OCL, Ribeiro-Alves M, Kehdy FSG, Neves PCDC, Bayma C, da Silva J, de Souza AF, Muller M, de Andrade EF, Andrade ACM, Dos Santos EM, Xavier JR, Maia MLS, Meireles RP, Cuni HN, Sander GB, Picon PD, Matos DCS, Moraes MO. Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha. Front Cell Infect Microbiol 2021;11:656393. [PMID: 34307188 DOI: 10.3389/fcimb.2021.656393] [Reference Citation Analysis]
5 Mahmoud K, Swidan S, El-nabarawi M, Teaima M. Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01309-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Abdolvahab MH, Darvishi B, Zarei M, Majidzadeh-A K, Farahmand L. Interferons: role in cancer therapy. Immunotherapy 2020;12:833-55. [PMID: 32635782 DOI: 10.2217/imt-2019-0217] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
7 Yeh ML, Huang JF, Dai CY, Yu ML, Chuang WL. Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B. Expert Opin Drug Metab Toxicol. 2019;15:779-785. [PMID: 31593639 DOI: 10.1080/17425255.2019.1678584] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]